Retatrutide is supplied strictly as a laboratory research material. It is not approved, intended or authorised for human consumption or any therapeutic use. This article is written for qualified researchers and is not medical advice. No dosing guidance is given or implied.
What is Retatrutide?
Retatrutide — Eli Lilly development code LY3437943 — is a synthetic peptide and the first single molecule to act as a triple agonist at three metabolic receptors at once. At roughly 4,731 Da, it is a mid-sized peptide engineered with a fatty-acid chain that extends its circulating time, giving a half-life of about six days and a once-weekly research cadence. It remains an investigational compound: it is not an approved medicine and is not authorised for human use anywhere in the world. For a fuller primer on the molecule, see our explainer on what Retatrutide is.
The triple GIP/GLP-1/glucagon mechanism
Most incretin-class peptides studied to date target one or two receptors. Semaglutide is a GLP-1 agonist; Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide goes a step further, engaging three receptors simultaneously:
- GLP-1 (glucagon-like peptide-1). The pathway that underpins the whole incretin class — associated in research with appetite and glucose-handling signalling.
- GIP (glucose-dependent insulinotropic polypeptide). A second incretin axis that appears to complement GLP-1 activity, the same pair Tirzepatide targets.
- Glucagon receptor. The distinguishing third arm. Glucagon-receptor activity is associated in research models with energy expenditure and hepatic lipid metabolism — the component that sets Retatrutide apart from the dual agonists.
It is this third, glucagon arm that makes Retatrutide the most-discussed molecule in current metabolic research, and the reason it cannot simply be treated as "another GLP-1."
What the TRIUMPH-1 data showed
The result that turned an obscure code number into a headline came from the Phase 2 TRIUMPH-1 programme, published in the New England Journal of Medicine in 2023. In that trial the highest study arm reported approximately 24.2% body-weight reduction at 12 mg over 48 weeks — the largest effect reported for any compound in the incretin class to date, and notably the curve had not plateaued when the study period ended. Those figures are the reason Retatrutide is watched so closely; they are trial observations reported for scientific context only and are not a claim about any outcome in any other setting.
Why UK research demand is surging
Interest in Retatrutide UK has climbed steeply through 2026. Search volume for "reta UK" and "buy retatrutide uk" has risen alongside the wider coverage of the triple-agonist mechanism, and UK laboratories evaluating the incretin class increasingly want the newest and most potent tool in it. The challenge is that demand has run well ahead of reliable supply, and a wave of new sellers has appeared to meet it — not all of them able to stand behind what they ship. For the practical sourcing side of that story, our companion piece on where to buy Retatrutide in the UK goes deeper.
Strengths available
Retatrutide is supplied by the milligram as a sterile lyophilised (freeze-dried) powder in a sealed vial. Research vials typically range from 5 mg entry sizes up to 60 mg best-value vials. Smaller vials suit short evaluations and method development; larger vials give the best cost per milligram for extended work. At RS Bio Labs all eight strengths are stocked, each independently tested to ≥99% purity with a per-batch Certificate of Analysis.
Compound: Retatrutide (LY3437943) · Class: triple GIP/GLP-1/glucagon receptor agonist · Molecular weight: ~4,731 Da · Half-life: ~6 days (weekly cadence) · Form: lyophilised powder · Status: investigational, not approved for human use.
Handling: reconstitution and storage
Lyophilised Retatrutide is stable but must be handled correctly. Before use it is reconstituted with bacteriostatic water, added slowly against the side of the vial rather than directly onto the powder, then swirled — never shaken — until fully dissolved. The volume of water you add sets the working concentration, so the ratio matters; our reconstitution guide walks through it step by step. Sealed lyophilised vials are best kept cold and out of light; once reconstituted, material is stored refrigerated and used within its stable window. Because clearance is slow, understanding the ~6-day half-life is central to designing any sound research timeline.
How to source it properly
Four things genuinely matter when you source reta UK labs can trust — everything else is noise:
- Purity ≥99%. Verified by independent HPLC, not the seller's own say-so.
- A per-batch COA. A real Certificate of Analysis ties a specific batch to its test results. If a supplier can't produce one per batch, walk away.
- Genuine UK dispatch. UK-based dispatch means faster delivery, no customs lottery, and someone accountable if something goes wrong.
- Correct presentation. A properly sealed lyophilised vial, cold-packed where needed — and a supplier that never makes a human-use or dosing claim.
The bottom line
Retatrutide (LY3437943) is the first triple GIP/GLP-1/glucagon agonist, posted the largest Phase 2 effect in its class, and is — for now — the most sought-after research peptide in the UK. Sourcing it well comes down to the same discipline as any serious reagent: insist on ≥99% purity, a per-batch COA, and real UK dispatch, treat any human-use claim as a disqualifier, and handle the lyophilised material correctly. Get those right and you have research-grade Retatrutide UK work can actually be built on.